- Home
- INDP vs BRTX Comparison
INDP vs BRTX Comparison
Compare INDP & BRTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INDP
- BRTX
- Stock Information
- Founded
- INDP 2000
- BRTX 1997
- Country
- INDP United States
- BRTX United States
- Employees
- INDP N/A
- BRTX N/A
- Industry
- INDP Biotechnology: Pharmaceutical Preparations
- BRTX Managed Health Care
- Sector
- INDP Health Care
- BRTX Health Care
- Exchange
- INDP Nasdaq
- BRTX Nasdaq
- Market Cap
- INDP 12.1M
- BRTX 11.3M
- IPO Year
- INDP N/A
- BRTX N/A
- Fundamental
- Price
- INDP $1.13
- BRTX $1.53
- Analyst Decision
- INDP Strong Buy
- BRTX Strong Buy
- Analyst Count
- INDP 2
- BRTX 1
- Target Price
- INDP $8.50
- BRTX $18.00
- AVG Volume (30 Days)
- INDP 305.3K
- BRTX 32.9K
- Earning Date
- INDP 11-12-2024
- BRTX 11-12-2024
- Dividend Yield
- INDP N/A
- BRTX N/A
- EPS Growth
- INDP N/A
- BRTX N/A
- EPS
- INDP N/A
- BRTX N/A
- Revenue
- INDP N/A
- BRTX $377,000.00
- Revenue This Year
- INDP N/A
- BRTX $598.90
- Revenue Next Year
- INDP N/A
- BRTX $162.81
- P/E Ratio
- INDP N/A
- BRTX N/A
- Revenue Growth
- INDP N/A
- BRTX 189.55
- 52 Week Low
- INDP $1.03
- BRTX $1.03
- 52 Week High
- INDP $3.10
- BRTX $3.67
- Technical
- Relative Strength Index (RSI)
- INDP 42.20
- BRTX 42.22
- Support Level
- INDP $1.11
- BRTX $1.44
- Resistance Level
- INDP $1.31
- BRTX $1.78
- Average True Range (ATR)
- INDP 0.10
- BRTX 0.16
- MACD
- INDP -0.01
- BRTX -0.00
- Stochastic Oscillator
- INDP 14.34
- BRTX 35.56
About INDP Indaptus Therapeutics Inc.
Indaptus Therapeutics Inc is a pre-clinical biotechnology company engaged in developing a novel and patented systemically-administered anti-cancer and anti-viral immunotherapy. It has developed a proprietary platform that exploits bacteria's natural ability to activate both innate and adaptive cellular immune pathways. The company's pre-clinical candidate Decoy20, has the ability to elicit single-agent activity and durable anti-tumor responses in the combination setting against colorectal, hepatocellular, pancreatic carcinoma, and non-Hodgkin's lymphoma models.
About BRTX BioRestorative Therapies Inc. (NV)
BioRestorative Therapies Inc is a biotechnology company based in the United States. It focuses on the development of regenerative medicine products and therapies using cell and tissue protocols, primarily involving adult (non-embryonic) stem cells. The company's two core development programs include the Disc/Spine Program, which involves cell therapy candidate, BRTX-100, a product formulated from autologous cultured mesenchymal stem cells collected from the patient's bone marrow; and the Metabolic Program, which includes the development of cell-based therapy to target obesity and metabolic disorders using brown adipose-derived stem cells, to generate brown adipose tissue.